A staggering 400 million people worldwide live with atopic dermatitis according to the latest Nature Reviews Disease Primers update published in June 2026. This corrected and expanded analysis represents a comprehensive reassessment of global AD prevalence, with high-income countries accounting for approximately 272 million cases, middle-income countries 96 million, and low-income countries 32 million.
Perhaps more concerning, approximately 140 million individuals experience moderate-to-severe disease requiring intensive management. The 2026 primer not only quantifies this unprecedented burden but also documents the emerging therapeutic landscape that has transformed since the original 2018 publication. The update incorporates refined endotype classification and evidence-based treatment algorithms reflecting the availability of biologic agents and targeted small-molecule inhibitors, offering clinicians and policymakers data-driven guidance for addressing this major chronic inflammatory condition.
Read the full article on GMJ Newsroom.
Was this article helpful?
